What is Lonapegsomatropin?
Lonapegsomatropin (brand name SKYTROFA, also called TransCon hGH) is a once-weekly long-acting PEGylated prodrug of recombinant human growth hormone. It was the first long-acting growth hormone approved in the United States and remains the most-used weekly GH replacement option for both children and adults.
The molecule consists of unmodified somatropin (the same 191-amino-acid recombinant hGH used in daily-dosed products) covalently attached to a 4-arm, 40 kDa PEG via Ascendis Pharma's proprietary TransCon linker. The linker is a self-cleaving carbamate that hydrolyzes auto-catalytically at physiologic pH and temperature, releasing native, unmodified somatropin at a controlled rate matching the body's natural GH clearance.
Mechanism of Action
- Sustained release of native hGH — the TransCon linker hydrolyzes over ~7 days, releasing free somatropin
- GH receptor activation — released somatropin engages the same GH receptor as daily hGH, activating JAK2-STAT5 signaling and producing IGF-1 in liver
- Equivalent active species — the active drug is native unmodified hGH; not a PEG-conjugated GH analogue (this differentiates lonapegsomatropin from somapacitan and other PEG- or albumin-conjugated GH variants)
A core design principle of TransCon products is that the released drug is structurally identical to the native peptide — the PEG and linker leave the active hormone unchanged. This avoids the immunogenicity, altered receptor pharmacology, and tissue-distribution differences seen with chemically modified peptide analogues.
Clinical Evidence
heiGHt Phase 3 (pediatric GHD, JCEM 2021):
- 161 treatment-naive children with GHD randomized to once-weekly lonapegsomatropin or daily somatropin for 52 weeks
- Annualized height velocity: 11.2 cm/year (lonapegsomatropin) vs 10.3 cm/year (daily) — non-inferior, numerically superior
- IGF-1 SDS profile within physiologic range
foresiGHt Phase 3 (adult GHD, JCEM 2025):
- 259 adults with GHD randomized to weekly lonapegsomatropin, daily somatropin, or placebo for 38 weeks
- Trunk fat reduction primary endpoint: −1.6% lonapegsomatropin vs +0.8% placebo (p<0.001)
- IGF-1 normalization comparable to daily GH; quality-of-life improvements
Approval History
- August 25, 2021 — FDA approval for pediatric growth hormone deficiency in children ≥1 year and ≥11.5 kg
- July 28, 2025 — FDA expanded approval for adult growth hormone deficiency
- EMA approved — January 2022
Distinction from Other Long-Acting GH Products
| Product | Active Species | Modification | Dosing |
|---|---|---|---|
| Lonapegsomatropin (Skytrofa) | Native unmodified hGH | TransCon prodrug, PEG cleaves off | Once weekly |
| Somapacitan (Sogroya) | Modified hGH (Lys141 acylation) | Albumin-binding fatty acid linker | Once weekly |
| Somatrogon (Ngenla) | Modified hGH (CTP fusion) | C-terminal hCG peptide extension | Once weekly |
| Daily somatropin (multiple brands) | Native hGH | None | Daily |
Lonapegsomatropin is the only weekly option that releases unmodified native GH; the others are GH analogues with altered structures.
Place in Therapy
Lonapegsomatropin is administered as a once-weekly subcutaneous injection via a single-use pen device. The weekly dosing reduces injection burden by 86% vs daily GH, which is particularly valuable for pediatric adherence and adult GHD where chronic compliance is a problem.
Safety Profile
Adverse events are largely the same as daily somatropin: arthralgia, peripheral edema, headache, and injection-site reactions. There is no signal for tumorigenesis or diabetogenic effects beyond what is seen with daily hGH.
Relationship to HGH and Other GH Peptides
Lonapegsomatropin is distinct from:
- Native hGH (somatropin) in our database — same active hormone, but daily vs weekly delivery
- Sermorelin, CJC-1295, GHRP-2/6, Hexarelin, Ipamorelin, MK-677, Tesamorelin — these are growth hormone secretagogues that stimulate the body to release its own GH; lonapegsomatropin is exogenous GH replacement
- Macimorelin — a GHRH analogue used for diagnostic testing of GHD, not for GHD treatment